Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Haselmeier is a drug-delivery device company focused on the design, development, industrialization, and manufacture of subcutaneous self-injection systems for pharmaceutical and biotechnology customers. Its portfolio includes pen injectors, autoinjectors, reconstitution systems, and connected adherence-enabled delivery solutions, with products such as D-Flex and PiccoJect. The company operates as a medmix brand and provides services spanning concept design, prototyping, testing, manufacturing, packaging, labeling, and serialization. Historically known as Wilhelm Haselmeier, the business was acquired by Sulzer in 2020 and now sits within medmix following the 2021 spin-off. It is not a therapeutic drug developer; rather, it is a commercial medical device and drug-delivery partner serving life science companies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Wilhelm Haselmeier.